Chemotherapy-associated steatohepatitis.
Meunier L, Larrey D.
Ann Hepatol. 2020 Nov-Dec;19(6):597-601. doi: 10.1016/j.aohep.2019.11.012. Epub 2020 Jan 30.
Tamoxifen-induced steatohepatitis.
Pratt DS, Knox TA, Erban J.
Ann Intern Med. 1995 Aug 1;123(3):236. doi: 10.7326/0003-4819-123-3-199508010-00018.
Tamoxifen-induced steatohepatitis.
Van Hoof M, Rahier J, Horsmans Y.
Ann Intern Med. 1996 May 1;124(9):855-6. doi: 10.7326/0003-4819-124-9-199605010-00015.
Tamoxifen induced hepatotoxicity via gut microbiota-mediated hyodeoxycholic acid depletion and Farnesoid X receptor signaling disruption.
Chen Y, Du H, Zhou W, Qin M, Li M, Jin Y, Xu Y, Ma C, Xia J, Mo Y, Chen N, Huang H, Li H, Xie Z, Wang P, Hong Y.
Gut Microbes. 2026 Dec 31;18(1):2610077. doi: 10.1080/19490976.2025.2610077. Epub 2026 Jan 2.
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E, Rienda I, Perez-Rojas J, Rapisarda A, Garcia-Llorens G, Jover R, Castell JV.
Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203.
Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience.
Patel R, Jin C, Jaber D, Casasanta N, Jain M, Fu W, Wu C, Moshier E, Tiersten A.
Clin Breast Cancer. 2025 Apr;25(3):283-290. doi: 10.1016/j.clbc.2024.12.020. Epub 2024 Dec 31.
Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
Osman KA, Osman MM, Ahmed MH.
Expert Opin Drug Saf. 2007 Jan;6(1):1-4. doi: 10.1517/14740338.6.1.1.
Drugs and steatohepatitis.
Farrell GC.
Semin Liver Dis. 2002;22(2):185-94. doi: 10.1055/s-2002-30106.
Tamoxifen-induced hepatotoxicity.
Ahbeddou N, Belbaraka R, Fetohi M, Errihani H.
Indian J Cancer. 2011 Jul-Sep;48(3):385. doi: 10.4103/0019-509X.84935.
NASH in Nondiabetic Endocrine Disorders.
Wang T, Yang W, Karakas S, Sarkar S.
Metab Syndr Relat Disord. 2018 Sep;16(7):315-320. doi: 10.1089/met.2018.0044. Epub 2018 Jun 6.
